Publications by authors named "Wei Xing Guo"
Objective: Clinically significant portal hypertension (CSPH) seriously affects the feasibility and safety of surgical treatment for hepatocellular carcinoma (HCC) patients. The aim of this study was to establish a new surgical scheme defining risk classification of post-hepatectomy liver failure (PHLF) to facilitate the surgical decision-making and identify suitable candidates for individual hepatectomy among HCC patients with CSPH.
Backgrounds: Hepatectomy is the preferred treatment for HCC.
Purpose: Laparoscopic isolated caudate lobectomy is still a challenging operation for surgeons. The access route of the operation plays a vital role during laparoscopic caudate lobectomy. There are few references regarding this technique.
View Article and Find Full Text PDFBackground: This study aimed to compare the survival outcomes of patients with initially unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) who underwent or did not undergo salvage surgery followed by a triple combination conversion treatment consisted of locoregional treatment (LRT), tyrosine kinase inhibitors (TKIs), and anti-PD-1 antibodies.
Methods: The data from 93 consecutive patients with initially unresectable HCC and PVTT across 4 medical centers were retrospectively reviewed. They were converted successfully by the triple combination treatment and underwent or did not undergo salvage resection.
Hepatocellular carcinoma (HCC), particularly when accompanied by microvascular invasion (MVI), has a markedly high risk of recurrence after liver resection. Adjuvant immunotherapy is considered a promising avenue. This multicenter, open-label, randomized, controlled, phase 2 trial was conducted at six hospitals in China to assess the efficacy and safety of adjuvant sintilimab, a programmed cell death protein 1 inhibitor, in these patients.
View Article and Find Full Text PDFObjectives: To observe the effects on the glucose-lipid metabolism and the expression of zinc-α2-glycoprotein (ZAG) and glucose transporter 4 (GLUT4) in the femoral quadriceps and adipose tissue after electroacupuncture (EA) at "Pishu" (BL 20), "Weiwanxiashu" (EX-B 3), "Zusanli" (ST 36) and "Sanyinjiao" (SP 6) in the rats with diabetes mellitus type 2 (T2DM), so as to explore the effect mechanism of EA in treatment of T2DM.
Methods: Twelve ZDF male rats were fed with high-sugar and high-fat fodder, Purina #5008 for 4 weeks to induce T2DM model. After successfully modeled, the rats were randomly divided into a model group and an EA group, with 6 rats in each one.
Background: Robotic hepatectomy (RH) is currently widely accepted and it is associated with some benefits when compared to open hepatectomy (OH). However, whether such benefits can still be achieved for patients with large hepatocellular carcinoma (HCC) remain unclear. This study aimed to evaluate the short-term and long-term outcomes of patients undergoing RH or OH.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the survival outcomes between patients with HBV-related hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) who received postoperative aspirin and those who had surgery alone.
- It involved 80 patients divided into two groups: one receiving adjuvant aspirin after surgery and the other having only the surgical procedure.
- Results showed that while overall survival rates were similar, the group taking aspirin had a significantly longer time before recurrence of PVTT, suggesting that aspirin may provide additional benefits post-surgery.
Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of hepatocellular carcinoma (HCC). However, long-term survival outcomes and treatment response of HCC patients undergoing immunotherapy is unpredictable. The study aimed to evaluate the role of alpha-fetoprotein (AFP) combined with neutrophil-to-lymphocyte ratio (NLR) to predict the prognosis and treatment response of HCC patients receiving ICIs.
View Article and Find Full Text PDFObjective: To observe the effect of electroacupuncture (EA) on liver protein kinase B (Akt)/forkhead box transcription factor 1 (FoxO1) signaling pathway in Zucker diabetic fatty (ZDF) rats, and to explore the possible mechanism of EA on improving liver insulin resistance of type 2 diabetes mellitus.
Methods: Twelve male 2-month-old ZDF rats were fed with high-fat diet for 4 weeks to establish diabetes model. After modeling, the rats were randomly divided into a model group and an EA group, with 6 rats in each group.
Advanced biliary tract cancer (BTC) has a poor prognosis, even after combined chemotherapy of gemcitabine and oxaliplatin (GEMOX). To investigate the efficacy and safety of GEMOX chemotherapy combining atezolizumab and bevacizumab in advanced BTC, the authors designed an open-label, single-arm, phase II clinical trial and will enroll patients with stage IV BTC. The participants will receive GEMOX chemotherapy combined with atezolizumab plus bevacizumab.
View Article and Find Full Text PDFPurpose: This study aimed at analyzing and comparing the perioperative results and long-term oncological outcomes of hepatocellular carcinoma (HCC) patients with type 2 diabetes mellitus (T2DM) treated with laparoscopic (LLR) versus open liver resection (OLR).
Methods: Clinicopathological data of HCC patients with T2DM who underwent LLR or OLR as initial treatment from four medical centers were retrospectively reviewed. The survival outcomes of patients who underwent laparoscopic liver resection (LLR) were compared with those of patients who underwent open liver resection (OLR).
Background: Anti-programmed cell death ligand 1/vascular endothelial growth factor inhibition, coupled with chemotherapy, may potentiate antitumor immunity leading to enhanced clinical benefit, but it has not been investigated in advanced biliary tract cancer (BTC).
Objectives: We investigated the efficacy and safety of atezolizumab, bevacizumab, and gemcitabine plus oxaliplatin (GEMOX) in advanced BTC and explore the potential biomarkers related to the response.
Design: Multicenter, single-arm, retrospective study.
Article Synopsis
- A study was conducted to compare the effectiveness and safety of three treatment options for unresectable recurrent hepatocellular carcinoma (HCC): transarterial chemoembolization combined with lenvatinib and PD-1 inhibitors (T-L-P), TACE with lenvatinib (T-L), and TACE alone.
- Among 204 patients analyzed, those in the T-L-P group had the best survival outcomes and disease control rates compared to the other two groups.
- The study concluded that the T-L-P regimen is both safe and significantly better in enhancing survival for patients dealing with unresectable recurrent HCC.
Background: The differences in short- and long-term outcome between laparoscopic liver resection (LLR) and open liver resection (OLR) for BCLC stage A large hepatocellular carcinoma (HCC) in difficult segments (I, IVa, VII, VIII) remain unclear. This PSM two-centre study aimed to compare perioperative and long-term survival outcomes of LLR with OLR for this HCC.
Methods: HCC patients with BCLC stage A who underwent OLR or LLR in two medical centres were enrolled in the study.
Article Synopsis
- Early and late recurrence of hepatocellular carcinoma (HCC) shows different outcomes, and determining the early recurrence timeframe is crucial, particularly for patients with microvascular invasion (MVI).
- The study analyzed 292 patients to establish the early recurrence interval and confirmed the results with an additional 421 patients using survival analysis techniques, identifying MVI as a significant risk factor.
- Findings suggest that for HCC patients with MVI, a 13-month period post-surgery is a practical early recurrence cutoff, and adjuvant TACE treatment during this time can improve survival rates compared to surgery alone.
Background: The effect of type 2 diabetes mellitus (T2DM) on survival of patients with hepatocellular carcinoma (HCC) after laparoscopic liver resection (LLR) has not been reported. This study aimed to explore the relationship between preoperative T2DM and long-term prognosis in HCC patients undergoing LLR.
Methods: HCC patients receiving LLR as initial treatment at four cancer centers were retrospectively included in this study.
Introduction: Vascular invasion and metastasis are poor prognostic factors in patients with hepatocellular carcinoma (HCC). The efficacy of available therapeutic regimens for unresectable HCC is not satisfactory in HCC with portal vein tumour thrombosis (PVTT). Therefore, this open-label, single-arm phase II clinical trial aims to investigate the efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating HCC patients with PVTT.
View Article and Find Full Text PDFBackground: Portal vein tumour thrombus (PVTT) in patients with hepatocellular carcinoma (HCC) is known as a major complication associated with poor survival. We clinically defined a new and rare type of HCC, PVTT-type HCC (PVTT-HCC), in a small group of HCC patients with HCC presenting only as PVTT without a demonstrable parenchyma tumour. The clinicopathological and biological features of PVTT-HCC are not clear.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluated a combined treatment approach for patients with unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT), using transarterial chemoembolization (TACE), antiangiogenic therapy, and PD-1 inhibitors.
- - Results from 39 patients showed an objective response rate of 35.9% and a disease control rate of 74.4%, with median overall survival at 14 months and progression-free survival at 9.2 months.
- - Most patients (87.2%) experienced treatment-related adverse events, primarily hypertension and decreased albumin levels, but there were no treatment-related deaths in this cohort.
A Double Suspension Technique for Laparoscopic Isolated Caudate Lobectomy.
J Laparoendosc Adv Surg Tech A
October 2022
Laparoscopic isolated caudate lobectomy is still a challenging procedure for hepatobiliary surgeons because of its deep location and narrow operating space. Hilar exposure and adequate operation space play an important role during laparoscopic caudate lobectomy. Very few references are available on this technique, and in this study, we present a new suspension technique to assist laparoscopic caudate lobectomy.
View Article and Find Full Text PDFThe therapeutic effect of transcatheter arterial chemoembolization (TACE) is limited for patients with hepatocellular carcinoma (HCC). Herein, we designed an open-label, single-arm phase II clinical trial to investigate the efficacy and safety of TACE combined with atezolizumab plus bevacizumab for patients with Barcelona Clinic Liver Cancer (BCLC) stage-B HCC. Patients will initially receive TACE.
View Article and Find Full Text PDFPurpose: To analyze the long-term oncological outcomes of Barcelona Clinic Liver Cancer (BCLC) stages 0-A hepatocellular carcinoma (HCC) patients associated with or without microvascular invasion (MVI) treated with laparoscopic versus laparotomic liver resection.
Methods: Clinicopathological data of HCC patients with BCLC stages 0-A from four medical centers were retrospectively reviewed. The survival outcomes of patients who underwent laparoscopic hepatectomy were compared with those who underwent laparotomic hepatectomy.
Finding a way to comprehensively integrate the presence and grade of clinically significant portal hypertension, amount of preserved liver function and extent of hepatectomy into the guidelines for choosing appropriate candidates to hepatectomy remained challenging. This study sheds light on these issues to facilitate precise surgical decisions for clinicians. Independent risk factors associated with grade B/C post-hepatectomy liver failure were identified by stochastic forest algorithm and logistic regression in hepatitis B virus-related hepatocellular carcinoma patients.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on comparing the long-term outcomes of liver resection (LR) and transcatheter arterial chemoembolization (TACE) for patients with hepatocellular carcinoma (HCC) complicated by bile duct tumor thrombus (BDTT).
- Analysis included 145 HCC patients with BDTT, where the LR group showed significantly longer overall survival (OS) and disease-free survival (DFS) than the TACE group both before and after statistical adjustment for other factors.
- The conclusion emphasizes that if surgery is an option, liver resection is a more effective treatment for improving prognosis in HCC patients with BDTT compared to TACE.